23.29

2.92% -0.70

After Hours: 23.28 -0.010 -0.04%

Celldex Therapeutics Inc (CLDX)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Celldex Therapeutics Inc stock is traded at $23.29, with a volume of 722.16K. It is down -2.92% in the last 24 hours and down -12.38% over the past month. Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.

Previous Close:

$23.99

Open:

$24.01

24h Volume:

722.16K

Relative Volume:

0.76

Market Cap:

$1.55B

Revenue:

$9.98M

Net Income/Loss:

$-154.08M

P/E Ratio:

-9.0271

EPS:

-2.58

Net Cash Flow:

$-159.66M

1W Performance:

-7.80%

1M Performance:

-12.38%

6M Performance:

-30.50%

1Y Performance:

-37.39%

1-Day Range:

$23.25

$24.06

1-Week Range:

$22.89

$25.89

52-Week Range:

$22.16

$53.18

Celldex Therapeutics Inc Stock (CLDX) Company Profile

Name

Celldex Therapeutics Inc

Sector

Healthcare (1177)

Industry

Biotechnology (679)

Phone

908-200-7500

Address

53 FRONTAGE ROAD, HAMPTON

Employee

160

Twitter

@search?q=celldex

Next Earnings Date

2024-11-04

Latest SEC Filings

CLDX's Discussions on Twitter

Compare CLDX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CLDX Celldex Therapeutics Inc	23.29	1.55B	9.98M	-154.08M	-159.66M	-2.58
VRTX Vertex Pharmaceuticals Inc	481.16	123.91B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	722.07	78.94B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	657.97	39.98B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	278.25	35.89B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	119.94	28.75B	3.30B	-501.07M	1.03B	-2.1146

Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-07-24	Initiated	Citigroup	Buy
Sep-30-24	Initiated	Goldman	Neutral
Sep-27-24	Downgrade	Wolfe Research	Outperform → Peer Perform
Jun-18-24	Initiated	Stifel	Buy
Jun-11-24	Initiated	Wolfe Research	Outperform
Dec-20-23	Initiated	TD Cowen	Outperform
Nov-10-23	Upgrade	Wells Fargo	Underweight → Equal Weight
Aug-22-23	Initiated	Wells Fargo	Underweight
Sep-17-21	Initiated	Jefferies	Buy
Sep-10-21	Initiated	SVB Leerink	Outperform
Jul-22-21	Initiated	Guggenheim	Buy
Feb-21-20	Initiated	Cantor Fitzgerald	Overweight
Aug-01-17	Resumed	H.C. Wainwright	Buy
Nov-07-16	Initiated	Aegis Capital	Buy
Mar-08-16	Downgrade	Jefferies	Buy → Hold
Mar-07-16	Downgrade	Guggenheim	Buy → Neutral
Mar-07-16	Downgrade	Leerink Partners	Outperform → Mkt Perform
Mar-07-16	Downgrade	Wedbush	Outperform → Neutral
Mar-01-16	Initiated	H.C. Wainwright	Buy
Aug-11-15	Reiterated	Brean Capital	Buy
Aug-11-15	Reiterated	Oppenheimer	Outperform
Aug-11-15	Reiterated	ROTH Capital	Buy
Jun-02-15	Reiterated	WBB Securities	Strong Buy
Nov-17-14	Reiterated	ROTH Capital	Buy
Mar-04-14	Reiterated	Oppenheimer	Outperform
Jul-08-13	Reiterated	Cantor Fitzgerald	Buy
Mar-08-13	Reiterated	Cantor Fitzgerald	Buy
Feb-26-13	Reiterated	Oppenheimer	Outperform
Jan-10-13	Reiterated	Cantor Fitzgerald	Buy
Oct-02-12	Reiterated	Oppenheimer	Outperform
Sep-14-12	Reiterated	Cantor Fitzgerald	Buy

View All

Celldex Therapeutics Inc Stock (CLDX) Latest News

Feb 06, 2025

It is Poised to be a Bull Market for Celldex Therapeutics Inc (CLDX) - SETE News

Feb 06, 2025

Feb 05, 2025

Post-Trade Analysis: Celldex Therapeutics Inc (CLDX) Slides -2.11, Closing at 23.15 - The Dwinnex

Feb 05, 2025

Chronic Spontaneous Urticaria Market Set to Grow Substantially - openPR

Feb 05, 2025